We demonstrate that PS-341, a small molecule inhibitor of the proteasome, markedly sensitizes resistant prostate, colon, and bladder cancer cells to TNF-like apoptosisinducing ligand (TRAIL)-induced apoptosis irrespective of Bcl-xL overexpression. PS-341 treatment by itself does not affect the levels of Bax, Bak, caspases 3 and 8, c-Flip or FADD, but elevates levels of TRAIL receptors DR4 and DR5. This increase in receptor protein levels is associated with the ubiquitination of the DR5 protein.
Introduction
TNF-like apoptosis-inducing ligand (TRAIL) and PS-341 are two novel anticancer agents with differing mechanisms of action. TRAIL induces apoptosis by first binding to two closely related receptors DR4 and DR5, causing the formation of a death-inducing signaling complex (DISC), which includes the receptors, the adaptor protein FADD, and caspase 8 (Medema et al., 1997) . Autoactivated caspase 8 is capable of cleaving procaspase 3 directly or digesting Bid to its active form (tBid), which leads to the release of cytochrome c from the mitochondria (Li et al., 1998; Luo et al., 1998; Gross et al., 1999) . PS-341 is a small molecule inhibitor of the proteasome that induces apoptotic cell death (Teicher et al., 1999) . Although treatment with this compound causes marked increases in a large number of cellular proteins , including c-myc and the cyclin-dependent protein kinase inhibitor p21 WAF1 , it is not clear how this agent actually induces apoptosis. Tumor cells that do not express p53 or p21 still die when incubated with this agent . PS-341 inhibits the activation of NF-kB (Sunwoo et al., 2001) . NF-kB plays a role in controlling the levels of inhibitor of apoptosis proteins, IAPs ; however, the regulation of NF-kB activity has not been directly linked to a specific mechanism by which PS-341 induces apoptosis. Through an unknown mechanism, PS-341 treatment of tumor cells overcomes drug resistance, and can enhance the killing activity of both dexamethasone and chemotherapeutic agents (Cusack et al., 2001; Hideshima et al., 2001) . This effect would appear additive and not synergistic.
Despite widespread expression of TRAIL receptors, many tumor cell lines are either partially or completely resistant to apoptotic cell death induced by this agent (Hao et al., 2001; Pawlowski et al., 2001) . Resistance results from a number of factors including the absence of caspase 8 (Grotzer et al., 2000) , increased AKT activity resulting from deletion of the PTEN phosphatase , or the absence of Bax (Deng et al., 2002) . In addition, overexpression of Bcl-2 family members blocks TRAIL-induced apoptosis (Munshi et al., 2001; Roklin et al., 2001) . The observation that the majority of TRAIL-resistant cell lines can be made TRAIL sensitive by treatment with protein synthesis inhibitors (Rieger et al., 1998; Wajant et al., 2000) implies that additional mechanisms regulating TRAIL resistance may exist.
Our results indicate that PS-341 and TRAIL synergize to kill TRAIL-insensitive tumor cell lines, including those overexpressing Bcl-xL or deficient in Bax, but is much less effective in cells lacking Bak. The effects of PS-341 appear to be mediated by its ability to enhance TRAIL-stimulated cleavage of caspase 8, which may be correlated with increased expression of TRAIL recep-tors DR4 and DR5. Our results suggest that this combination of agents may be useful therapeutically in killing tumor cells with multiple abnormalities in the apoptotic pathway.
Materials and methods

Cell lines and reagents
The human prostatic carcinoma cell line LNCaP and bladder JCA-1 cells were cultured in RPMI 1640 (Gibco BRL, Rockville, MD, USA) supplemented with 10% FBS, 100 U/ml penicillin/100 mg/ml streptomycin. HCT-116, HC-4, and murine embryonic fibroblasts (MEF) were cultured in DMEM (Gibco BRL, Rockville, MD, USA) supplemented with 10% FBS, 100 U/ml penicillin/100 mg/ml streptomycin. MEF were frozen at passage 2 and used at the first passage after thawing. Antibodies were obtained from the following sources: DR4 and DR5 antibodies, Alexis (San Diego, CA, USA); ubiquitin antibodies, Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA); Bcl-2, caspase 8, Upstate Biotechnology (Lake Placid, NY, USA); Poly ADP ribose polymerase (PARP), Trevigen (Gaithersburg, MD, USA); P21 waf1 and FADD antibodies, BD Transduction Laboratories (San Jose, CA, USA); SMAC and myc antibodies, University of Colorado Health Science Center Monoclonal Antibody Core Facility (Denver, CO, USA); FLAG agarose, FLAG and HA antibodies, Sigma Chemical Co. PS-341 was a gift of Millennium, Inc. (Cambridge, MA, USA). The FLAG-DR5 L334N expression vector was constructed as follows: the sequence corresponding to residues 56-411 of mature human DR5 was amplified from a template supplied by Genentech. This sequence was inserted into the expression vector pFLAG-CMV1 (Sigma) to provide an N-terminal signal peptide from preprotrypsin and the FLAG epitope. The L334N mutation in the death domain was then made with the QuickChange kit (Stratagene), and the entire epitope-bearing sequence transferred to the episomal vector pCEP4 (Invitrogen). The integrity of the construct was verified by DNA sequencing.
Recombinant human TRAIL
TRAIL cDNA was subcloned into the pET-15b vector (Novagen, Madison, WI, USA) and used to transform Escherichia coli strain BL21 (Promega, Madison, WI, USA). Recombinant human TRAIL was purified on a Ni-NTA agarose column (Qiagen, Valencia, CA, USA) after cell lysis in 50 mm sodium phosphate pH 8.0, 300 mm NaCl, 1 mm PMSF, 5 mm 2-mercaptoethanol, and 2.5% Triton X-100.
Cell viability assays
To measure cell viability, LNCaP and LNCaP-Bcl-xL cells were plated in 96-well plates at 10 000 cells/well and incubated overnight. The cells were then treated with varying amounts of DMSO, PS-341, TRAIL, or the combination. After a 16 h incubation at 371C, MTS substrates (Cell TITER 96 Aqueous Assay, Promega, Madison, WI, USA) were added according to protocol, and absorbance at 490 nm was measured with a nMax Kinetic Plate Reader (Molecular Devices, Sunnyvale, CA, USA). For assays employing 4 0 ,6-diamido-2-phenylindole (DAPI), cells were plated in six-well plates 24 h prior to treatments. At the end of the treatment period, cells were washed, trypsinized, centrifuged, and resuspended in 0.05 ml complete medium containing 1 mg/ml DAPI. All components of the harvesting step (culture medium, washes, and trypsinized cells) were combined before centrifugation to ensure recovery of unattached cells. Cells were examined and nuclei with apoptotic morphology were counted using a Zeiss Axiophot fluorescence microscope with an appropriate filter at Â 400 magnification. DAPI experiments were performed in duplicate and a minimum of 300 cells per sample were scored.
Western blot analysis
Cell lines were plated in six-well plates and treated with appropriate amounts of DMSO as a control, PS-341, or TRAIL under a variety of conditions. The cells were then lysed in SDS-PAGE sample buffer (15% glycerol, 0.125 m Tris-HCl, pH 6.8, 5 mm EDTA, 2% SDS, 0.1% bromophenol blue, 1% 2-mercaptoethanol), and incubated for 10 min at room temperature. The lysate was then boiled for 5 min and frozen at À801C. Western blots were carried out as described previously .
Quantitative RT-PCR
Quantitative RT-PCR assays were performed using the ABI 5700 real-time system with SYBR-green fluorescence, as described in detail (Drabkin et al., 2002) . Briefly, cDNA was synthesized from 2.5 mg of total RNA isolated by the method of Chomczynski and Sacchi (1987) with Superscript II (Invitrogen Life Technologies, Carlsbad, CA, USA) using random primers and conditions recommended by the manufacturer. For quantitative RT-PCR, 20 ml reactions were utilized, which included 1 ml cDNA, 1.6 mm MgCl 2 , 200 mm deoxyribonucleotide triphosphates, 0.1 mm primers, and 0.1 ml AmpliTaq Gold (Applied Biosystems, Wellesley, MA, USA). Following an initial 951C 10 min incubation to activate the polymerase, 40 cycles of a two-stage PCR were performed consisting of 951C Â 15 s and 601C Â 1 min. Duplicate reactions were performed that invariably agreed within 1/2 cycle. RNA used for cDNA synthesis was measured both by optical density and gel electrophoresis followed by densitometric scanning. PCR products were verified by gel analysis. Absence of contamination was verified by the use of no template controls and mock cDNA synthesis reactions without reverse transcriptase. Data were analysed with GeneAmp 5700 SDS software. Primers were DR4F: ATGGCGCCACCAC-CAGCTAGAG; DR4R: GGAGGTAGGGAGCGCTCCTC-GG; DR5F: ATCACCCAACAAGACCTAGC; DR5R: CA-CCTGGTGCAGCGCAAGCAG. Semiquantitative PCR for DR5 was performed with cDNAs prepared as above. Primers were DR5F: GGGAAGAAGATTCTCCTGAGATGT; DR-5R: ACATTGTCCTCAGCCCCAGGTCG, which span the splice junction (Screaton et al., 1997) .
Isolation of TRAIL receptors DR4 and DR5
Cells were detached from plates by incubation with Hank's Basic Salt Solution supplemented with 2 mm EDTA and 2 mm EGTA. The isolation was performed in two ways. (1) For isolation of total cellular receptors, cells were pelleted, washed in PBS, and lysed in TGH buffer (50 mm HEPES pH 7.2, 1% Triton X-100, 10% glycerol, 100 mm NaCl, 1 mm NaF, 1 mm EDTA, 1 mm EGTA, 0.25 mm phenylmethylsulfonylfluoride, and protease inhibitors) for 15 min on ice. Lysates were centrifuged for 30 min at 100 000 g. Histidine-tagged TRAIL prepared as described above was added at 1 mg/ml to the supernatants, which were incubated for 20 min on ice. Antihistidine antibody coupled to agarose beads (Sigma) was added to the supernatants, which were then incubated with rotation for 2 h to overnight at 41C. Beads were washed thoroughly with TGH buffer and eluted twice with 100 mm glycine (pH 2.3) for 10 min on ice. Following addition of concentrated SDS-PAGE sample buffer, the eluates were neutralized with 1 n NaOH and boiled for 5 min prior to electrophoresis. (2) For isolation of cell surface receptors and associated DISC components, following detachment from culture dishes, cells were pelleted and resuspended in culture medium set aside from the individual treatments. Histidinetagged TRAIL was added to 1 mg/ml and the cells were incubated at 371 for 20 min with agitation. After assessment of viability by trypan blue exclusion, cells were pelleted, washed, lysed, and centrifuged as described above. The remainder of the procedure was as described except that TRAIL was not added to the cell lysates. Before the addition of anti-histidine agarose, the protein content of the lysates was determined and volumes adjusted to equalize protein content.
Cytosolic SMAC levels
Cytosolic extracts from HC-4, HCT-116, and LNCaP cells were prepared by the procedure originally described by BossyWetzel et al. (1998) as modified by Nesterov et al. (2001) . Briefly, 10-cm plates of cells near-confluence were scraped directly into cell culture medium and pelleted for 5 min at 200 g. Cells were washed once in 1 ml phosphate-buffered saline (PBS) and resuspended in 0.35 ml HT buffer (220 mm mannitol, 68 mm sucrose, 50 mm PIPES-KOH pH 7.4, 50 mm KCl, 5 mm EDTA, 2 mm MgCl 2 , 0.25 mm phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, 10 mg/ml leupeptin) by vortexing. After 45 min on ice, cells were revortexed and passed 10 times through a 25 gauge needle. Following 10 min centrifugation at 200 g, the supernatant was cleared by centrifugation for 30 min at 100 000 g and analysed for SMAC protein by Western blotting.
Nucleosome assay
LNCaP cells were grown to confluency in 10-cm plates. They were then treated with DMSO, 1 mm PS-341, 100 ng/ml TRAIL, or a combination of PS-341 and TRAIL. The following day, the cells were collected via trypsinization, pelleted and lysed according to the Nucleosome ELISA kit (Oncogene Research Products, Boston, MA, USA). The subsequent assay was carried out as directed.
Crystal violet staining
HCT-116 and HC-4 cells were plated in 24-well plates and grown to confluency. They were then treated with varying concentrations of PS-341 and/or TRAIL. Medium was gently aspirated and cells were washed in 1 Â PBS. Crystal violet stain was prepared with 0.1% crystal violet in ddH 2 O and added to wells until stain covered the bottom of the wells. The plates were then incubated at room temperature for 10 min. The stain was then gently aspirated and the wells were washed three times with 1 Â PBS.
X-Gal staining of caspase 8-transfected cells
HCT-116 and HC-4 cells were plated in six-well plates and grown to approximately 50% confluency. They were then cotransfected with 0.2 mg LacZ plasmid (Invitrogen) and 0.2 mg Fkp-caspase 8 (180) plasmid (a gift of Dr David Baltimore, California Institute of Technology, Pasadena, CA, USA). The cells were incubated for 24 h and stained with X-Gal. The experiment was performed in triplicate and repeated twice.
Results
To determine whether PS-341 enhances the ability of TRAIL to induce cell death, LNCaP human prostate cancer cells were incubated with either TRAIL, PS-341, or the combination for 24 h and a cell viability (MTS) assay was carried out. LNCaP cells showed no change in viability after treatment with either PS-341 or TRAIL, but the combination of both led to significant decrease in viability (Figure 1a ). Using the analysis of Chou and Talalay (1983) , the combination of these two agents was found to be highly synergistic (data not shown). To establish that the decrease in viability was caused by induction of programmed cell death (apoptosis), an ELISA assay was performed, which measures free cleaved nucleosomes generated during apoptosis. Only addition of both PS-341 and TRAIL, but not TRAIL or PS-341 alone, induced increases in free nucleosomes ( Figure 1b) . Similar results were obtained with multiple prostate cancer cell lines, including PC-3 and DU-145 cells (data not shown).
To evaluate the possibility that the failure of PS-341 alone to kill LNCaP cells reflected an inability of the drug to penetrate these cells, levels of specific cellular proteins after treatment were measured. Since PS-341 inhibits proteasome degradation, we expected to see an increase in ubiquinated proteins. An 18 h treatment of LNCaP cells with PS-341 caused marked increases in total ubiquinated proteins, as well as two proteins normally degraded by the proteasome system, p21
WAF-1 and c-myc (Figure 1c ), whereas there was no change in the levels of PARP protein. It is possible that the increase in p21
WAF-1 seen when incubation with PS-341 is compared to the combined treatment may come from an increased ability to extract this protein in cells undergoing apoptosis. Only the combination of PS-341 plus TRAIL, but not PS-341 alone, induced the cleavage of PARP (Figure 1c) , consistent with the ability of these agents when combined to induce apoptosis.
Overexpression of Bcl-2 family members blocks TRAIL-induced cell death (Munshi et al., 2001; Roklin et al., 2001) , and release of SMAC and cytochrome c from mitochondria. To test whether PS-341 could overcome this block, LNCaP prostate cancer cells overexpressing the Bcl-xL protein were incubated with PS-341, TRAIL, or the combination (Figure 2a) . Approximately threefold overexpression of Bcl-xL compared to parental LNCaP cells was verified (data not shown). MTS assay results demonstrated that whereas each agent alone was unable to decrease cell viability, the combination was able to overcome Bcl-xL overexpression, leading to marked decrease in cell viability. Parallel experiments demonstrated that only the combination of PS-341 and TRAIL resulted in the appearance of SMAC protein in cytosolic extracts of these cells (data not shown).
TRAIL-induced cleavage of Bid to tBid enables the translocation of Bax protein into mitochondria followed by the release of cytochrome c and induction of apoptosis (Wei et al., 2001) . To investigate whether TRAIL and PS-341 could induce the death of cells that (Figure 2b ) that the addition of either 0.1 or 1 mm PS-341 had no or minimal effect on these cells, whereas the addition of PS-341 enabled TRAIL to kill the HC-4 cells, and lowered the concentration of TRAIL necessary to kill HCT-116 cells. Like HC-4 cells, DU-145 human prostate cancer cells also contain a frame-shift mutation in Bax. These cells also demonstrated a combined response of TRAIL and PS-341 (data not shown).
To test whether PS-341 enhances TRAIL-mediated apoptosis by upregulating proteins in the TRAIL pathway, we examined the levels of specific proteins in the pathway after treatment with each agent alone or together. In LNCaP cells, PS-341 did not induce changes in the levels of FADD, Bak, or Bax ( Figure 3a) ; or caspases 3, 8 or XIAP (data not shown). Although levels of caspase 8 and FADD were unchanged after PS-341 treatment, we found that overnight treatment of LNCaP cells with PS-341 and TRAIL resulted in increased cleavage of caspase 8, as evidenced by elevated levels of 41, 43, and 18 kDa cleavage products (Figure 3b ). This increase in caspase 8 cleavage was associated with a decrease in levels of Bid (Figure 3b) , a caspase 8 substrate, and activation of the effector caspases 3 and 7 (data not shown). Quantitation of these Western blots using scanning densitometry demonstrated a 50% increase in the levels of the 18 kD caspase 8 fragment with the combined treatment compared to treatment with TRAIL alone. Similar results were obtained with the JCA-1 human bladder cancer cell line (Figure 3c ). The figure shows that in the presence of PS-341 the extent of caspase 8 and Bid cleavage is directly related to the dose of TRAIL applied.
Recent evidence suggests that c-FLIP plays an important role in TRAIL sensitivity, and that downregulation of functional c-FLIP in response to doxorubicin treatment (Kelly et al., 2002) , cell differentiation (Hietakangas et al., 2003) , or phosphorylation (Higuchi et al., 2003) increases sensitivity to TRAIL-mediated apoptosis. In addition, FLIP is subject to ubiquitination and proteasomal degradation (Kim et al., 2002) . To determine the role of FLIP in PS-341 action, we examined levels of c-FLIP-L and c-FLIP-S in HC-4 and LNCaP cells using an antibody that recognizes both forms of c-FLIP (Scaffidi et al., 1999) . The results are shown in Figure 3d . In both cell lines, c-FLIP L , and c-FLIP S appear upregulated in response to PS-341. In addition, the levels of the p43 cleavage product appear equivalent in samples treated with TRAIL or the combination of PS-341 and TRAIL. These data do not suggest a role for c-FLIP in PS-341-mediated sensitization to TRAIL.
It was shown that after treatment with TRAIL, HCT-116, but not HC-4 (Bax negative), cells responded with mitochondrial release of SMAC protein (Deng et al., 2002) . However, HC-4 cells transfected with SMAC were able to undergo TRAIL-induced cell death, demonstrating that SMAC is sufficient for TRAILinduced death in these cells (Deng et al., 2002) . The addition of TRAIL alone to HC-4 and HCT-116 causes similar levels of caspase 8 and Bid cleavage (Deng et al., 2002, Figure 4a) , suggesting that the difference in the ability of these cells to die may be regulated by levels of Bax. In contrast, others have shown a difference in the extent of cleavage of caspase 8 by TRAIL in these two cell lines (LeBlanc et al., 2002) . As in LNCaP and JCA-1 cells, the combination of PS-341 and TRAIL induced increased cleavage of caspase 8 and Bid ( Figure 4a ). As expected, neither TRAIL nor PS-341 addition in isolation was sufficient to cause release of SMAC (Figure 4a The requirement for SMAC protein in TRAILinduced death of HC-4 cells prompted us to ask whether PS-341 required cytochrome c-activated caspase 9 to potentiate TRAIL-induced death. For this purpose, we used caspase 9-deficient MEF (Hakem et al., 1998) . Wild-type MEF release cytochrome c and SMAC in response to combination treatment with PS-341 and TRAIL (data not shown). To test whether the absence of caspase 9 would block the effect of combined agents, wild-type and caspase 9-deficient MEF were exposed for 18 h to TRAIL, PS-341, or the combination, and analysed for cell death by DAPI uptake. As shown in Figure 5 , both wild-type and caspase 9-deficient MEF underwent apoptosis to a similar degree in response to combination treatment of PS-341 and TRAIL, indicating that caspase 9 is dispensable for the potentiating effect.
To evaluate whether increased activation of caspase 8 by TRAIL and PS-341 was sufficient to induce cell death, we transfected HC-4 and HCT-116 cells with a vector that expressed the catalytic portion of the caspase 8 molecule cloned in frame with three repeats of the FK506 binding protein (FKBP12) (Fkp-caspase 8) (Yang et al., 1998) . Overexpression of this protein in the absence of crosslinking was sufficient to induce apoptotic cell death in 293 cells (data not shown), although crosslinking of the FK506 sequences enhances the ability of this protein to induce cell death (Yang et al., 1998) . We used X-Gal staining of LacZtransfected cells as a marker of those cells expressing À/À MEF were exposed to vehicle, 0.1 mm PS-341, 1 mg/ml TRAIL, or the combination for 18 h. Cells were processed for DAPI uptake as described in Materials and methods. Data are expressed as mean and range of two independent experiments PS-341 treatment overcomes TRAIL resistance TR Johnson et al transfected Fkp-caspase 8. We found that the overexpression of activated caspase 8 in HC-4 cells was able to induce apoptosis and that the level of apoptosis, although slightly less than in HCT-116, was not significantly different than in this parental cell line ( Figure 6 ). Thus, in the absence of Bax, increased levels of activated caspase 8 are sufficient to induce apoptosis of these colon cancer cells.
Since the combination of PS-341 and TRAIL increased caspase 8 activation, we evaluated the ability of PS-341 to affect the levels of TRAIL receptors DR5 and DR4. HC-4 cells were incubated with PS-341 alone for varying periods of time. The cells were then either incubated with histidine-tagged TRAIL and lysed to measure cell surface receptors, or lysed followed by addition of histidine-tagged TRAIL to measure wholecell receptor levels. Both DR5 and DR4 receptors were then immunoprecipitated with antihistidine antibody. Controls were not treated with histidine-tagged TRAIL, although the rest of the procedure was followed. In contrast to PS-341's lack of effect on levels of TRAIL pathway proteins downstream from TRAIL receptors, incubation of HC-4 cells with PS-341 alone resulted in marked accumulation of TRAIL receptor DR5 and to a lesser extent DR4 both in whole-cell lysates and (as shown, Figure 7a ) on the cell surface protein. After 3 h treatment with PS-341, approximately the time HC-4 cells with apoptotic morphology begin to appear in cultures treated with the combination of PS-341 and TRAIL, DR5 receptors are reproducibly elevated (51713%, n ¼ 4), while 18 h treatment with PS-341 raised DR5 levels 4-8-fold. In comparison, DR4 levels did not increase appreciably by 3 h although an approximate doubling was observed after 18 h. Similar changes in DR5 and DR4 were obtained with treatment of PC-3 human prostate cancer cells with PS-341 (data not shown).
To determine whether the observed increases in these proteins were due to transcriptional activation, semiquantitative and quantitative real-time PCR was performed as described in Materials and methods. This technique was chosen over Northern analysis to avoid complications arising from the high degree of sequence similarity between the receptors (MacFarlane et al., 1997) . Figure 7b shows semiquantitative RT-PCR of cDNA from HC-4 cells exposed to PS-341 for varying amounts of time, using primers specific for DR5. The same cDNAs were subjected to quantitative real-time PCR and the DCt values (relative to cDNA from control cells) are indicated beneath the corresponding lanes. The results indicate an early increase in DR5 mRNA HC-4 cells were exposed to vehicle or PS-341 for 6 h. At this point, cycloheximide (50 mm) was added and incubation was continued for an additional 18 h. Total cellular TRAIL receptors were isolated as described in Materials and methods and subjected to Western analysis for DR4 and DR5. The lane labeled 'No TRAIL' is as in (a) PS-341 treatment overcomes TRAIL resistance TR Johnson et al transcripts of about twofold, consistent with the observed rise in DR5 protein, with maximal increases of 6-8-fold at 6 and 12 h followed by a return to baseline.
To address the possibility that PS-341 increased protein stability and thus contributed to accumulation of DR4 and DR5, receptor levels were determined following exposure of HC-4 cells to cycloheximide. An example of such an experiment is shown in Figure 7c . In the presence of PS-341, DR5 levels were unchanged after 18 h of cycloheximide treatment; in the absence of PS-341, levels decreased by 2.5-fold, suggesting that PS-341 treatment prevented the degradation of this protein.
Attempts to determine the half-life of DR4 and DR5 by pulse-chase experiments utilizing 35 S-methionine proved difficult to interpret due to nonspecific binding of labeled proteins to the antihistidine antibody in the critical molecular weight range. Thus, our data suggest transcriptional activation at early time points, and protein accumulation secondary to decreased degradation.
The increased stability of DR5 in the presence of PS-341 prompted us to examine whether this receptor might be ubiquitinated. To investigate this possibility, a FLAG-tagged DR5 construct containing an inactivating mutation in the death domain to prevent the induction of apoptosis was cotransfected into 293 T cells with a cDNA expressing HA-tagged ubiquitin. Following treatments, DR5 was recovered by immunoprecipitation with anti-FLAG antibody coupled to agarose beads and analysed by Western blotting. The results are shown in Figure 8 . High molecular weight forms of DR5 were detected with antibodies against HA, and were greatly increased by treatment with PS-341, thus demonstrating the enhanced ubiquitination of this protein.
Since HC-4 cells are transformed human colon cancer cells and might contain additional mutations in the apoptotic pathway in addition to the lack of Bax, we wanted to assess the sensitivity of normal cells, also devoid of Bax, to this combination of agents. In addition, it was reported that either Bax or Bak can mediate sensitivity to tBid-induced apoptosis (Wei et al., 2001) , suggesting that cells devoid of Bak should have a similar phenotype to those that were Bax-negative. We Figure 8 Ubiquitination of DR5. Expression vectors containing FLAG-tagged DR5 (L334N) (FLAG-DR5), HA-tagged ubiquitin (HA-Ub), or empty vector were transfected into 293 T cells in the combinations indicated. After 24 h, PS-341 (1 mm) or vehicle was added and the cultures were incubated overnight. Cell lysates were incubated overnight with anti-FLAG antibody covalently coupled to agarose beads at 41. Bound material was eluted and prepared for Western blotting as described for DR5 immunoprecipitation. Blots were stained for DR5 (FLAG) or ubiquitin (HA) as indicated 
Discussion
The ability of PS-341 to enhance TRAIL-induced cell death is not tumor-type specific and was seen by us in LNCaP cells; two additional prostate cancer cell lines, DU-145 and PC-3; in the bladder cancer cell lines JCA-1 and TSU-PR (Van Bokhoven et al., 2001) ; in the colon cancer cell line HC-4; and in MEF. The ability of proteasome inhibitors, including PS-341, to stimulate TRAIL-induced apoptosis has also been reported in other cell lines (Mitsiades et al., 2001; Franco et al., 2001) .
The effects of TRAIL on induction of apoptosis in human prostate cancer cells are known to be blocked by overexpression of Bcl-2 or Bcl-xL (Munshi et al., 2001; Roklin et al., 2001) . However, we found that the combination of PS-341 and TRAIL overcame the block to mitochondrial participation in the apoptotic process mediated by overexpression of Bcl-xL. We obtained similar results in cells deficient in Bax or caspase 9. The mechanism allowing this effect appears to originate in part with the ability of PS-341 to increase the levels of both DR5 and DR4 receptors, leading to enhanced cleavage of caspase 8 and Bid, and increased release of SMAC and cytochrome c. Since this combination of agents is active in caspase 9-deficient MEF, it is likely that the apoptosome including cytochrome c, APAF-1, and caspase 9 is not needed for this effect and activated caspase 8 cleaves caspases 3 and 7 directly leading to the induction of apoptosis. Other agents, including sulindac (He et al., 2002) , and chemotherapeutic agents etoposide and camptothecin (Gibson et al., 2000; Nagane et al., 2000; Lacour et al., 2001; LeBlanc et al., 2002) , have been shown to enhance the ability of TRAIL to kill Baxnegative HC-4 cells (LeBlanc et al., 2002) presumably by inducing increases in DR5 but not DR4 TRAIL receptors. Quantitative PCR indicates that PS-341 induces a twofold increase in mRNA for DR5 at 2 h after treatment of HC-4 cells, increasing to eightfold by 12 h, suggesting that PS-341 controls the levels of DR5 in part through transcriptional mechanisms. Array experiments carried out by others after chemotherapy treatment of HC-4 cells have shown a similar level of increase in DR5 (LeBlanc et al., 2002) , but not DR4, while PS-341 treatment of myeloma cells caused no change in mRNA levels at 2 and 4 h but did induce an increase at 8 h (Mitsiades et al., 2002) .
The ubiquitin-proteasome pathway acts as a regulator of endocytosis of selected membrane receptors, for example, the growth hormone and epidermal growth factor receptors, and controls lysosomal degradation (Govers et al., 1999; Longva et al., 2002) of these receptors. It was shown that degradation of many ubiquitinated membrane proteins was slowed in the presence of proteasome inhibitors (van Kerkhov and Strous, 2001 ) and that mutational inactivation of the proteasome pathway prevented endocytosis of the growth hormone receptor and increased its abundance on the cell surface (van Kerkhov et al., 2002) . DR5 is known to be internalized into endosomes following exposure of cells to TRAIL (Zhang et al., 2000) . Our findings that DR5 is ubiquitinated and that PS-341 increased its stability suggest that similar mechanisms may be involved for these death receptors. Thus, PS-341 may enhance the number of TRAIL receptors both through protein stabilization and transcriptional mechanisms.
The effect of PS-341 on c-FLIP is of interest due to accumulating evidence of the importance of c-FLIP in receptor-mediated apoptosis. Both c-FLIP L and c-FLIP S have been shown to inhibit receptor-mediated apoptosis, apparently by different mechanisms (reviewed in Krueger et al., 2001) . Our data indicate that PS-341 does not downregulate levels of either form of FLIP, and that the combination of PS-341 and TRAIL does not alter the degree of c-FLIP L cleavage over that induced by TRAIL alone, even though caspase 8 cleavage is increased (Figures 3b,c and 4a ), It could be that FLIP is limiting while caspase 8 is not, thus allowing for greater caspase 8 activation in response to PS-341-induced upregulation of TRAIL receptors. Other mechanisms are possible, for example, c-FLIP phosphorylation (Higuchi et al., 2003) .
Experiments examining the ability of PS-341, TRAIL, or the combination of these agents to induce apoptosis in MEF missing Bax, Bak, or both proteins suggests an important role for these proteins in regulating apoptosis induced by these agents. Interestingly, wild-type MEF underwent moderate levels of apoptosis when incubated with PS-341 alone, but MEF missing either Bax or Bak were resistant. The mechanism by which PS-341 induces apoptosis is unknown. Suggestions have been made that modulation of NF-kB plays a role in its action . Recent array data (Mitsiades et al., 2002) suggest that PS-341 upregulates the levels of a number of caspases and decreases the levels of Bcl-2. Clearly, from these data the mitochondrial death pathway is necessary for PS-341-induced apoptosis. It is possible that PS-341 treatment activates a BH3 protein that binds to Bak or Bax to induce mitochondrial release of cytochrome c and other proapoptotic proteins.
We found that treatment with the combination of TRAIL and PS-341, as opposed to treatment with these compounds individually, triggered apoptosis much more effectively in MEF containing Bak. The combined treatment was significantly less effective in MEF lacking Bak, or both Bak and Bax. One explanation for our results is that a PS-341-induced increase in Bak protein is needed to enhance TRAIL-mediated apoptosis. The addition of etoposide to HC-4 cells was shown to stimulate a marked increase in Bak mRNA, although the actual protein levels were not measured (LeBlanc et al., 2002) . However, we observed no increase in Bak protein with PS-341 treatment in multiple cell types including LNCaP, HC-4, and MEF (data not shown). Whether the functions of Bak and Bax are completely interchangeable is not known. Bak-deficient T cells were resistant to apoptosis induced by staurosporine, etoposide, and bleomycin (Wang et al., 2001 ) and failed to release cytochrome c when transfected with Bid. Mandic et al. (2001) found that cisplatin induced the proapoptotic conformation of Bak, but not of Bax, in three out of four melanoma cell lines, suggesting some specificity in signaling to Bak. However, in baby mouse kidney cells, the presence of either Bak or Bax was sufficient to allow for TNF a-induced apoptosis (Degenhardt et al., 2002) . Both Bax or Bak-deficient MEF were sensitive to the killing effects of tBid (Wei et al., 2001) , the activated form of Bid, and BimS , suggesting that these proteins were interchangeable in inducing the death pathway. It is possible that PS-341 regulates a BH3 domain protein which preferentially binds to Bak to induce apoptosis. Further experiments are needed to clarify this hypothesis.
Our data suggest a model whereby PS-341 enhances TRAIL killing by increasing the level of DR5 and DR4 receptors, thus increasing caspase 8 activation. As suggested by the induction of apoptosis in bax À/À bak À/À and caspase 9-deficient MEF, mitochondria may not be necessary for apoptosis induced by PS-341 and TRAIL; caspase 8 may directly cleave caspases 3 and 7 causing cell death. In the presence of Bak, however, the mitochondria are activated to release cytochrome c, SMAC, and other proteins that serve to amplify the signal from TRAIL receptors. The observation that caspase 9-deficient MEF are still responsive to this combination is consistent with previous experiments (Deng et al., 2002) , suggesting that SMAC upregulation alone is sufficient for increased sensitivity to TRAIL. SMAC would function to further increase the activation of caspases 3 and 7.
Our data demonstrate that the combination of PS-341 and TRAIL should be active in treating human tumors with multiple abnormalities in the apoptotic cascade.
Abbreviations TRAIL, TNF-like apoptosis-inducing ligand; DISC, deathinducing signaling complex; PARP, polyADP ribose polymerase; MEF, murine embryonic fibroblasts.
